This section assesses the plan from the perspectives that matter most to lenders and equity investors: debt-service cover, capital efficiency, and risk-adjusted returns, with the occupancy ramp as the central sensitivity and a clear-eyed treatment of the J-curve, the moderate returns and the severe downside inherent in a capital-intensive build.
Debt-service cover and capital efficiency
|
Metric |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
CFADS |
14 |
38 |
85 |
155 |
247 |
|
Debt service |
17 |
49 |
78 |
176 |
219 |
|
DSCR (x) |
0.84x |
0.78x |
1.10x |
0.88x |
1.13x |
|
Net debt / EBITDA (x) |
9.68x |
4.84x |
3.61x |
3.14x |
2.57x |
|
ROCE |
-1.9% |
-0.3% |
1.2% |
3.3% |
6.2% |
Analyst flagDebt-service cover is below 1.0x during the ramp — structure accordingly
This is a critical honest finding. Because the model is capital-intensive and follows a J-curve, cash flow available for debt service does not cover scheduled debt service in the ramp years, DSCR sits below 1.0x before recovering as EBITDA scales. A conventional amortising loan would breach cover early. The plan therefore requires a development-finance structure built for infrastructure: a principal grace period through the ramp, a funded debt-service reserve, conservative gearing, and ideally government or DFI credit support. Lenders should size and structure the debt to the mature cash flow, not the ramp, and equity must carry the early years. This is standard for greenfield healthcare infrastructure, but it must be structured in from the start.
Returns — moderate, infrastructure-grade and long-dated
On the sponsor’s outlook, revenue of R1.1 billion at a 25% EBITDA margin, exited at a 10.5x EV/EBITDA multiple on Year-5 EBITDA of R275 million, the plan delivers a project IRR near 22%, an equity IRR of about 20%, and a money multiple around 1.7x. These are moderate, infrastructure-grade returns, appropriate to a capital-intensive, long-dated healthcare build, and a world away from the high multiples of a capital-light clinic. Critically, the five-year exit understates the value: only five of the ten planned centres are open by Year 5 and they are still maturing, so much of the value accrues over the seven-to-ten-year build-out. A longer hold, or an exit multiple reflecting the completed-network pipeline, materially improves the outcome.
|
Occupancy / revenue vs plan |
80% |
90% |
100% |
110% |
120% |
|---|---|---|---|---|---|
|
Equity IRR |
8% |
14% |
20% |
25% |
29% |
Analyst flagRead the returns as moderate and the downside as severe
Three honest caveats attach to the returns. First, they are moderate by design, infrastructure-grade, not venture-grade, and much of the value is beyond Year 5, so this is a patient-capital investment. Second, the downside is severe: because the model is capital-intensive, a combined-stress scenario, a 20% weaker ramp, a 15% lower margin and an 8x exit, returns roughly negative 18%. Unlike a capital-light business, there is little natural cushion, so the plan must be underwritten conservatively. Third, every return figure is gated by the workforce and the payers: if therapists cannot be recruited or institutional payers do not contract reliably, the revenue, and the returns, do not materialise. Investors should underwrite the workforce, payer and funding plans, not the headline IRR.
Three-case scenario analysis
Framing the decision as three underwriteable cases is more honest than a single headline. The combined-stress case, a 20% weaker ramp, a 15% lower margin and an 8x exit, returns roughly negative 18%; the base case (the sponsor outlook at 10.5x) returns about 20%; the upside case (a stronger ramp at a premium multiple) is materially higher. The spread is wide because capital intensity amplifies both directions, which is precisely why the workforce, payer and funding risks must be underwritten before the base case can be relied upon.
|
Combined stress |
Base |
Upside |
|
|---|---|---|---|
|
Scenario |
Ramp –20%, margin –15%, 8x |
Sponsor outlook, 10.5x |
Ramp +20%, 15x |
|
Equity IRR |
-18% |
20% |
48% |
|
Assessment |
Genuinely negative |
Infrastructure-grade |
Strong |
Two-dimensional sensitivity — occupancy ramp and exit multiple
The two variables that most drive the equity return are the occupancy/revenue ramp (which sets mature EBITDA) and the exit multiple (which capitalises it). The grid below shows equity IRR across both simultaneously.
|
Ramp \\ Exit x |
8.0x |
10.5x |
13.0x |
15.0x |
|---|---|---|---|---|
|
80% ramp |
-8% |
8% |
19% |
27% |
|
90% ramp |
-1% |
14% |
25% |
33% |
|
100% ramp |
5% |
20% |
31% |
38% |
|
110% ramp |
10% |
25% |
36% |
43% |
|
120% ramp |
15% |
29% |
40% |
48% |
The grid underlines the profile: returns are respectable in the base and upside, but the bottom-left corner, a weak ramp exited at a low multiple, destroys value. The variables not on this grid, whether therapists can be recruited and whether institutional payers contract reliably, are the ones that most determine which column and row the plan lands in.
Indicative funding & covenant package
|
Covenant / structural feature |
Indicative level |
Rationale |
|---|---|---|
|
Principal grace period |
Through the ramp (to Year 3–4) |
DSCR is below 1.0x during the build |
|
Funded debt-service reserve |
6–12 months of debt service |
Bridges the J-curve cover shortfall |
|
Minimum DSCR (post-grace) |
≥ 1.20x once mature |
Sized to mature, not ramp, cash flow |
|
Multi-round funding condition |
Rounds committed pre-expansion |
National vision depends on staged capital |
|
Gearing cap |
Conservative through the build |
Equity carries the early years |
|
Occupancy / staffing covenant |
Monitored vs plan |
Early-warning on the binding constraints |
|
Dividend lock-up |
Until cover & leverage tests met |
Retains cash through the build |
Valuation and exit
The base case applies a 10.5x EV/EBITDA exit multiple to Year-5 EBITDA of R275 million, implying an enterprise value near R2.9 billion and equity value of roughly R2.2 billion after net debt. A healthcare-infrastructure multiple is appropriate, and 10.5x is reasonable for a purpose-built, contracted, high-impact network with a national build-out pipeline. Because only five of the ten planned centres are open and maturing by Year 5, the multiple also captures the pipeline value a strategic acquirer would pay for. Credible exit routes include a trade sale to a hospital or healthcare-infrastructure group, a development-finance or infrastructure-fund partnership, or a long-term hold generating growing, contracted cash flows, with the scarcity value of a built, staffed, national paediatric network the key attraction.
|
Exit metric |
Value |
|---|---|
|
Year-5 EBITDA |
~R275m |
|
Exit multiple (EV/EBITDA) |
10.5x |
|
Implied enterprise value |
~R2,888m |
|
Implied equity value (net of debt) |
~R2,181m |
|
Project IRR / equity IRR |
~22% / ~20% |
|
Money multiple (MOIC) |
~1.7x (long-dated) |
Financing process and next steps
- Financial close of the flagship funding (equity + development debt) to build and open the Johannesburg flagship and the national platform.
- Workforce due diligence — a credible plan to recruit, train and retain therapists and paediatric specialists, the single most important condition precedent.
- Anchor payer & referral contracts — government, medical-aid and hospital agreements to validate demand and de-risk the ramp.
- Multi-round funding path — a committed, staged, milestone-linked programme for the national rollout, ideally with DFI and government participation.